HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma

Adoptive cell therapy with NY-ESO-1-specific T cells is a promising option for the treatment of soft tissue sarcoma (STS) but achieves only transient tumor control in the majority of cases. A strategy to optimize this cell therapeutic approach might be the modulation of the expression of the cancer-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Wenjie, Wang, Lei, Schubert, Maria-Luisa, Kleist, Christian, Neuber, Brigitte, Wang, Sanmei, Yang, Mingya, Hückelhoven-Krauss, Angela, Wu, Depei, Schmitt, Anita, Müller-Tidow, Carsten, Shiku, Hiroshi, Schmitt, Michael, Sellner, Leopold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962361/
https://www.ncbi.nlm.nih.gov/pubmed/35203582
http://dx.doi.org/10.3390/biomedicines10020373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962361/
https://www.ncbi.nlm.nih.gov/pubmed/35203582
http://dx.doi.org/10.3390/biomedicines10020373

Ejemplares similares